On May 15, 2026, the National Medical Products Administration (NMPA) of China published Announcement No. 47 of 2026, issuing the long-awaited Implementation Measures for Drug Trial Data Protection. Effective immediately upon publication, these measures establish China's first operational regulatory data protection (RDP) registry after nearly two decades of legislative gaps. The new rules grant eligible chemical drugs and biological products up to six years of data protection, running from their marketing-authorization approval date in China.
Promulgated alongside the State Council’s revised Implementing Regulations of the Drug Administration Law (which also took effect on May 15, 2026), the new RDP framework represents a fundamental shift in China's pharmaceutical intellectual property (IP) architecture. It creates a robust administrative barrier designed to prevent competitors from relying on an originator’s undisclosed clinical trial data to secure rapid generic or biosimilar approvals.
However, to global regulatory strategists, launch planners, and business development (BD) teams, the 2026 measures require careful navigation. China's data protection is not an unconditional market monopoly. It operates under a reliance-based mechanism that carries critical exceptions—such as the self-generated-data pathway and the exclusion of bioequivalence data. Furthermore, protection is not granted automatically; manufacturers must actively apply, and failure to meet strict transitional deadlines can result in an immediate waiver of rights.
This article provides an in-depth analysis of the new RDP framework. It details the legislative foundation of the revised State Council regulations, traces the international treaty context back to WTO and TRIPS, analyzes the tiered protection periods by drug category, explains the reliance-based mechanism and its exceptions, outlines the transitional application timelines, and provides a strategic playbook for business development valuation and launch strategy.
Disclaimer: This analysis is intended for informational and strategic purposes for pharmaceutical professionals. It does not constitute investment, financial, or formal legal advice.
The Legislative Foundation: Revised Implementing Regulations
The Implementation Measures for Drug Trial Data Protection (NMPA Announcement No. 47 of 2026) must be read in tandem with the State Council decree signed on January 27, 2026, which issued the revised Implementing Regulations of the Drug Administration Law (effective May 15, 2026, comprising 9 chapters and 89 articles).
The revised regulations formally codify two distinct pillars of administrative exclusivity in China:
Article 21 (Market Exclusivity for Pediatric and Orphan Drugs)
This article introduces direct market exclusivity for specific categories. Eligible pediatric drugs receive up to two years of market exclusivity, while approved orphan drugs (drugs for rare diseases) can receive up to seven years of market exclusivity.
Crucially, the orphan exclusivity is contingent on the manufacturer maintaining a "stable commercial supply" in China. The NMPA defines this supply obligation to prevent companies from securing exclusivity blockades without actually launching or importing the drugs for Chinese patients. Unlike data protection, market exclusivity is an absolute block on the approval of any identical generic or competitor product, regardless of the competitor's data source.
Article 22 (Regulatory Data Protection)
This article establishes the legal basis for the six-year drug trial data protection regime. It dictates that the state will protect undisclosed trial data generated by marketing authorization holders. It prohibits subsequent generic applicants from unauthorized reliance on this protected data to obtain marketing approvals.
NMPA Announcement No. 47 of 2026 acts as the operational handbook that implements the broad principles of Article 22, detailing the specific application windows, review workflows, and categories of eligible drugs.
The International Context: TRIPS, WTO, and the Road to 2026
The establishment of the 2026 RDP measures represents the culmination of a multi-decade legislative journey that began when China joined the World Trade Organization (WTO) in 2001. Under Article 39.3 of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement), WTO members are obligated to protect undisclosed test or other data submitted to secure marketing approval for pharmaceutical or agricultural chemical products that utilize new chemical entities:
"Members, when requiring, as a condition of approving the marketing of pharmaceutical or of agricultural chemical products which utilize new chemical entities, the submission of undisclosed test or other data, the origination of which involves a considerable effort, shall protect such data against unfair commercial use."
China incorporated this principle into its domestic laws via the 2002 Drug Administration Law Implementing Regulations. However, the 2002 rules lacked clear definition and operational guidelines, resulting in a system where data protection was rarely applied or enforced in practice. Subsequent draft measures issued in 2018 and 2023 attempted to resolve this, but it was not until NMPA Announcement No. 47 of 2026 that a fully functional, registry-based enforcement system was established.
This transition brings China in line with international RDP standards, providing global innovators with the predictability required to license and launch advanced therapies in the region.
Tiered Protection Periods by NMPA Drug Category
The NMPA does not apply a single, uniform exclusivity block to all approved drugs. Instead, the 2026 measures establish a tiered protection period linked directly to the drug’s registration category under the NMPA framework.
The table below outlines the tiered data protection periods granted to eligible drug products under the new measures.
| NMPA Drug Registration Category | Description / Criteria | Data Protection Period |
|---|---|---|
| Category 1 (Chemical & Biologic) | Innovative drugs containing novel chemical structures or biologics that have not been marketed anywhere in the world. | 6 Years |
| Category 5.1 (Chemical) / 3.1 (Biologic) | Originator drugs approved overseas that are seeking their first domestic marketing authorization in China. | 6 Years |
| Category 2 (Chemical & Biologic) | Improved drugs (new formulations, new combinations, or new indications) that provide significant clinical advantages. | 4 Years |
| Category 5.1 (Chemical - Improved) | Improved overseas originator drugs seeking their first domestic approval in China. | 4 Years |
| Category 3 (Chemical) / 3.2 (Biologic) | First-to-file generic or biosimilar versions of overseas-approved originator drugs that are not yet available in the Chinese market. | 3 Years |
This tiered structure is designed to incentivize the launch of truly novel molecular entities and first-in-class biologics in China, while offering scaled protection for incremental clinical improvements.
The Reliance-Based Protection Mechanism vs. Market Exclusivity
To evaluate the commercial strength of the new RDP regime, compliance and strategy teams must understand how the reliance-based mechanism operates and identify the statutory carve-outs.
The Reliance Block
Under NMPA Announcement No. 47, during the active data protection period (e.g., six years for an innovative Category 1 drug):
- The NMPA and the Center for Drug Evaluation (CDE) are prohibited from approving any subsequent drug application (generic, biosimilar, or improved drug) that references or relies on the originator's protected trial data, unless the originator provides explicit, written consent.
- The CDE will refuse to accept generic applications that utilize the originator's clinical data to establish efficacy and safety.
This prevents "free-riding" by generic developers who seek to bypass clinical development by showing equivalence to the originator.
The Self-Generated-Data Exception
Crucially, RDP is not market exclusivity. Under the self-generated-data exception:
- If a competitor independently designs and conducts its own complete, non-relying preclinical and clinical trials (Phase I, II, and III) in China to demonstrate safety and efficacy, the competitor’s application can be accepted, reviewed, and approved by the NMPA during the originator's six-year protection window.
- The NMPA does not block the market; it only blocks reliance on the originator's proprietary data.
For high-volume generic developers or well-funded biosimilar sponsors, the self-generated-data exception remains an active pathway. If a biosimilar developer is willing to spend the capital to run a comparative Phase III trial in China, the six-year data protection period will not prevent their launch.
Bioequivalence (BE) and Vaccine Carve-Outs
The 2026 measures explicitly exclude certain data types from protection:
- Bioavailability (BA) and Bioequivalence (BE) Data: BE data generated for generic drugs is not eligible for protection. RDP only applies to preclinical and clinical trial data used to prove safety and efficacy.
- Vaccine Immunogenicity Data: Standard immunogenicity data for vaccines is excluded, reflecting public health priorities that demand rapid vaccine availability.
Critical Transitional Deadlines (June 5 & June 26)
RDP is not granted automatically upon drug approval. Manufacturers must actively file a data-protection request with the CDE. For drugs approved or pending prior to the May 15, 2026, effective date, the NMPA established a strict transitional window:
The June 5, 2026, Application Cutover
Under the implementation guidelines, any manufacturer holding a pending drug review or an already-approved eligible drug (approved within the six-year window prior to May 15, 2026) was required to submit their formal data-protection request to the CDE by June 5, 2026 (representing 15 working days from the announcement date).
The NMPA treated the June 5 deadline as a hard cutover. If a manufacturer failed to file the RDP request by 17:00 on June 5, 2026, the omission was treated as a voluntary waiver of data protection rights. The drug became immediately vulnerable to generic applications relying on the published clinical trial summaries.
The June 26, 2026, CDE-to-NMPA Notification
Following the receipt of transitional applications, the CDE conducted an accelerated audit of qualifications. By June 26, 2026, the CDE completed its review and formally notified the NMPA of the validated RDP candidates.
The NMPA subsequently published these granted protections on the CDE public registry. Once published, the NMPA is statutorily bound to reject any generic application referencing these assets unless the applicant proves they are utilizing the self-generated-data pathway.
Strategic Playbook for Business Development and Launch Strategy
The operationalization of the NMPA's data protection rules changes how global assets are valued and commercialized in China. BD and alliance management teams should integrate the following parameters into their China-market models:
1. In-Licensing Asset Valuation Models
When evaluating the in-licensing of a clinical-stage asset from a global biotech for the China region, BD teams must modify their revenue forecasts:
- Exclusivity Extension Beyond Patent Life: Calculate the "RDP extension window." If a drug's core compound patent expires in 2029, but it secures NMPA approval in 2027, the six-year data protection window extends exclusivity to 2033. Layered onto the exclusivity and patent-cliff timing already on the global calendar, this extra four-year window represents high-margin, generic-free revenue that must be incorporated into the Net Present Value (NPV) calculation.
- Verification of Category Eligibility: Ensure the asset’s registration category supports the 6-year block. If the asset is categorized as an "improved drug" (Category 2), the protection drops to 4 years. BD teams should adjust their royalty structures based on the confirmed NMPA category.
2. Launch Sequence Optimization
Global launch planners must evaluate the timing of China filings relative to US and EU filings. Under Category 5.1/3.1 rules:
- An overseas originator drug receives the full 6 years of data protection only if it is the first to be launched domestically in China.
- If the manufacturer delays the China filing, allowing a domestic developer to secure approval for a generic or biosimilar first, the originator loses the RDP filing priority.
- To secure the maximum protection, global originators should implement parallel clinical development in China (participating in Multi-Regional Clinical Trials [MRCTs]) to align China NMPA approval with FDA and EMA approvals.
3. Generic and Biosimilar Entry Decisions
For generic and biosimilar developers operating in China, the 2026 measures require a decision matrix that complements the broader generic-entry playbook:
- The Wait-and-See Path: If the originator has secured a 6-year RDP block, the generic sponsor can choose to wait out the exclusivity window, preparing their BE filings to submit immediately upon RDP expiration. This path requires minimal clinical trial expenditure but delays market entry.
- The Independent Trial Path: If the target market is large enough to justify the investment, the generic sponsor can choose to bypass the RDP block by conducting independent, head-to-head clinical trials. This path requires significant capital and clinical development expertise but offers the opportunity to launch years ahead of competitors who choose the wait-and-see path.
Comparison: China, US, and EU Data Exclusivity Frameworks
The 2026 China RDP regime combines elements of both the US and EU frameworks, but it remains distinct in its execution. For context on how market exclusivity works in the US and the underlying regulatory-exclusivity mechanics, the table below compares the regulatory data protection models of the three major pharmaceutical markets.
| Dimension | China NMPA Exclusivity (2026 No. 47) | US FDA Exclusivity (Hatch-Waxman) | EU EMA Exclusivity (8+2+1 Model) |
|---|---|---|---|
| NCE Exclusivity Period | 6 Years (NMPA Category 1) | 5 Years (Hatch-Waxman NCE) | 8 Years (Regulatory Data Protection) |
| Biologics Exclusivity | 6 Years (NMPA Category 1) | 12 Years (BPCI Act Exclusivity) | 8 Years (Standard RDP) |
| Independent Trial Exception | Yes (Self-generated-data pathway is open) | No (Generic/505(b)(2) cannot bypass active exclusivity via independent trials) | No (Generic/biosimilar cannot bypass standard RDP window via independent trials) |
| Orphan Exclusivity | 7 Years (Under revised Implementing Regulations Art. 21) | 7 Years (Orphan Drug Act) | 10 Years (Orphan Regulation) |
| Pediatric Exclusivity | 2 Years (Under revised Implementing Regulations Art. 21) | 6 Months (Best Pharmaceuticals for Children Act) | 6 Months (PIP extension to SPC) |
The most critical difference is that China’s RDP allows for the independent trial exception, whereas the US and EU systems do not. In the US and EU, during the active exclusivity window (such as the 12-year biologic exclusivity in the US), the FDA and EMA are prohibited from approving any biosimilar or generic, regardless of whether the competitor generated their own clinical trial data.
In China, the RDP block is strictly limited to data reliance. This makes the Chinese system more favorable to domestic generic developers who possess the clinical capabilities to run independent comparative trials.
Frequently Asked Questions (FAQ)
Does six-year data protection stop a generic that runs its own clinical trials from launching in China?
No. Unlike the US and EU frameworks, China's regulatory data protection is strictly a reliance-based block. If a competitor has the financial and clinical capacity to conduct independent, complete preclinical and clinical trials (Phase I, II, and III) in China to demonstrate safety and efficacy, the competitor’s application can be accepted, reviewed, and approved by the NMPA during the originator's six-year protection window.
Is data protection granted automatically when a drug is approved?
No. Data protection is not automatic. The Marketing Authorization Holder (MAH) must file a formal application with the CDE during the drug registration process, providing the necessary documentation to prove the trial data is undisclosed and was independently obtained. For existing drugs, the MAH had to file a request before the transitional deadline of June 5, 2026. Failure to file on time is treated as a waiver of RDP rights.
How does China's regime compare with US and EU data exclusivity?
China’s 6-year NCE protection is slightly longer than the US 5-year NCE protection but shorter than the EU’s 8-year RDP block. However, for biologics, China’s 6-year protection is significantly shorter than the US’s 12-year window. Crucially, the Chinese framework allows competitors to bypass the block by generating their own independent trial data, a pathway that is closed in both the US and EU during active exclusivity windows.
What documents must be submitted to the CDE to secure data protection?
To secure data protection, the MAH must submit a formal Drug Trial Data Protection Application Form along with supporting documentation that includes:
- Undisclosed Declaration: A formal statement certifying that the trial data has not been publicly disclosed or published in full.
- Self-Obtained Certification: Documentation proving that the MAH independently financed and conducted the trials (avoiding data sharing or reliance on third-party public registries).
- Registration Category Proof: Documents verifying the NMPA drug category (e.g., Category 1 or Category 5.1), which determines the applicable protection duration.
Can a pediatric drug receive both the 2-year market exclusivity and the 6-year data protection?
Yes. Under the revised Implementing Regulations, the 2-year pediatric market exclusivity (Article 21) and the 6-year drug trial data protection (Article 22) are separate administrative rights. An innovative pediatric drug that meets both criteria will receive the absolute market blockade under Article 21 for two years, while retaining the data reliance block under Article 22 for the full six years. This provides a layered defense during the initial years of launch.
What happens if an MAH misses the June 5 transitional deadline but still wants protection?
The CDE and NMPA have stated that the June 5, 2026, deadline for already-approved or pending Class 1 drugs was a strict statutory cutover. Missing this deadline is treated as an administrative waiver of RDP rights. Once waived, the MAH cannot retroactively apply for data protection for that specific approval. The drug remains protected only by its active patents and any other applicable exclusivity types, such as the pediatric or orphan exclusivity under Article 21.
How does the NMPA define "undisclosed data" for the purposes of Announcement No. 47?
Under the Measures, data is considered "undisclosed" if it has not been published in full academic journals, disclosed in public patent applications, or presented in public clinical registries prior to the date of the marketing application in China. If the originator has published the full patient-level clinical results in a global journal or disclosed the detailed datasets in open-access filings, a competitor can argue the data is no longer undisclosed, potentially disqualifying it from protection. Consequently, clinical development teams must carefully coordinate global publication timelines with China regulatory filings to ensure the "undisclosed" status of their trial data is not compromised before the NMPA RDP application is finalized.
Can a local licensee in China apply for trial data protection on behalf of a foreign MAH?
Yes. Under Chinese pharmaceutical administration law, the local licensee or regulatory representative appointed by a foreign Marketing Authorization Holder can manage the data protection application process. However, the application must still be filed in the name of the Marketing Authorization Holder, and the resulting data protection rights are legally held by the MAH, not the local licensee. The agreement between the foreign innovator and the Chinese commercial partner must explicitly define who manages the filing process and allocate liability for any delays or errors that could compromise the RDP status of the drug.
What is the relationship between NMPA data protection and the patent linkage system?
China's patent linkage system (established in 2021) and the 2026 regulatory data protection measures function as separate but complementary IP gates. Patent linkage resolves potential patent disputes before generic approval by allowing originators to file patent challenges against generic applications listed in the national patent information platform. RDP, on the other hand, is a strict administrative block handled directly by the CDE/NMPA during the review phase. Even if a generic sponsor successfully bypasses patent linkage (for example, if the compound patent has expired), the NMPA will still block the approval of the generic application if it relies on the originator's protected trial data during the active six-year data protection window.
Sources
- National Medical Products Administration (NMPA). Announcement on the Issuance of the Implementation Measures for Drug Trial Data Protection (No. 47 of 2026). Published and Effective May 15, 2026. NMPA Announcement No. 47 of 2026
- State Council of the People's Republic of China. Decree of the State Council: Revised Implementing Regulations of the Drug Administration Law. Signed January 27, 2026; Effective May 15, 2026. Published by the Ministry of Justice. State Council Implementing Regulations
- Ropes & Gray LLP. China's NMPA Issues Final Measures on Regulatory Data Protection. Insights & Alerts. Published May 2026. Ropes & Gray Legal Alert
- Bird & Bird. China Reveals Long-Awaited Regulatory Data Protection Rules. Insights. Published May 2026. Bird & Bird Insight
- Jones Day. China's New Regulatory Data Protection Regime Becomes Effective Immediately. Jones Day Publications. Published May 29, 2026. Jones Day Commentary
- China Patent Strategy. China Released Drug Trial Data Protection Implementation Measures and CDE Q&A Update. Published May 2026. China Patent Strategy Analysis
- Hogan Lovells. Pillars of Pharmaceutical IP: Regulatory Exclusivity Regime in China. Hogan Lovells Publications. Published 2026. Hogan Lovells Exclusivity Analysis
- U.S. Food and Drug Administration (FDA). Patents and Exclusivity in the Orange Book. FDA Patents and Exclusivity
